Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 5/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6750419 | 1.00 | NOS1 (0.52) | NOS1LTA4HMAOBPPARAMRGPRX4 | |
| SCHEMBL31706291 | 1.00 | NOS1 (0.52) | NOS1LTA4HMAOBPPARAMRGPRX4 | |
| SCHEMBL17233207 | 1.00 | NOS1 (0.52) | NOS1LTA4HMAOBPPARAMRGPRX4 | |
| SCHEMBL7248303 | 0.98 | NOS1 (0.51) | NOS1LTA4HMAOBPPARAMRGPRX4 | |
| SCHEMBL7152797 | 0.93 | NOS1 (0.48) | NOS1LTA4HMAOBPPARA | |
| SCHEMBL5317430 | 0.92 | NOS1 (0.50) | NOS1LTA4HMAOBPPARACHRNB2 | |
| SCHEMBL4332998 | 0.86 | LTA4H (0.50) | NOS1LTA4HMAOBPPARACHRNB2 | |
| SCHEMBL30720430 | 0.84 | PRMT1 (0.54) | — | |
| SCHEMBL14095592 | 0.84 | PRMT1 (0.54) | — | |
| SCHEMBL30209074 | 0.84 | PRMT1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197201-A1 | FLUOROSURFACTANTS | MERCK PATENT GESELLSCHAFT (DE) | 2009-08-06 | — | — | US | disclosed |
| EP-2035129-A1 | FLUOROSURFACTANTS | Merck Patent GmbH (DE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008003443-A1 | FLUOROSURFACTANTS | MERCK PATENT GMBH (DE) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197201-A1 | FLUOROSURFACTANTS | CBR3, SCO2, FPR3 | NOS1 1019/4885LTA4H 3480/4885MAOB 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.